Pfizer Inc (PFE)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $164.67B
Last updated: Nov 17, 2026 at 11:06 AM ET
Pfizer Inc (PFE) Stock Forecast
Analysts expect Pfizer (PFE) to earn $3.05 per share in the fiscal year ending Dec 31, 2026, on revenue of $63.13B. Of 28 analysts, 9 rate the stock Buy or Strong Buy, 17 Hold and 2 Sell or Strong Sell, for a consensus of Hold. For the fiscal year ending Dec 31, 2027, the EPS consensus is $2.95.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 28 ratings average 2.75, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 32% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 3.6% |
| Buy | 8 | 28.6% |
| Hold | 17 | 60.7% |
| Sell | 1 | 3.6% |
| Strong Sell | 1 | 3.6% |
- Consensus
- Hold
- Total analysts
- 28
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus falls 3.3% and revenue estimates fall 3.7%.
- Fiscal year ending Dec 31, 2026
- $3.05
- EPS consensus, revenue $63.13B
- Fiscal year ending Dec 31, 2027
- $2.95
- EPS consensus, revenue $60.82B
- Next report
- Feb 1, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $3.05 | $2.90 to $3.22 | 23 | $63.13B | $61.33B to $63.97B | 25 |
| Dec 31, 2027 | $2.95 | $2.54 to $3.18 | 24 | $60.82B | $58.68B to $63.10B | 25 |
Quarterly Estimates
The EPS consensus rises from $0.69 for the quarter ending Dec 31, 2026 to $0.70 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.69 | $0.62 to $0.87 | 20 | $17.37B | $16.25B to $18.80B | 18 |
| Mar 31, 2027 | $0.70 | $0.56 to $0.77 | 8 | $14.12B | $13.80B to $14.43B | 7 |
Estimate Revisions
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2027 | 15 | 4 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 2.3% from $2.98.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $3.05 | $3.04 | $2.96 | $2.98 | $2.98 | +2.5% |
| Fiscal year ending Dec 31, 2027 | $2.95 | $2.94 | $2.89 | $2.90 | $2.90 | +1.8% |
| Quarter ending Mar 31, 2027 | $0.70 | $0.70 | $0.68 | $0.67 | $0.67 | +4.1% |
Frequently Asked Questions About PFE
What is the PFE stock forecast?
Consensus analyst estimates put Pfizer's EPS at $3.05 for the fiscal year ending Dec 31, 2026, on revenue of $63.13B. The consensus rating from 28 analysts is Hold.
How do analysts rate PFE stock?
Of 28 analysts covering Pfizer, 1 rates it Strong Buy, 8 Buy, 17 Hold, 1 Sell and 1 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from PFE next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $3.05, with estimates from $2.90 to $3.22 from 23 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $2.95, with estimates from $2.54 to $3.18 from 24 analysts.
What revenue do analysts expect from Pfizer next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $63.13B, with estimates from $61.33B to $63.97B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $60.82B, with estimates from $58.68B to $63.10B.
How many analysts cover PFE?
28 analysts rate Pfizer stock, and 23 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
PFE pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts